BostonGene Corporation
BostonGene Corporation, headquartered in the United States, is a pioneering entity in the biotechnology industry, specialising in precision medicine and advanced genomic analysis. Founded in 2017, the company has rapidly established itself as a leader in the development of innovative solutions for cancer treatment, leveraging its proprietary algorithms and comprehensive data analytics. With a focus on personalised healthcare, BostonGene offers unique products and services that integrate genomic data with clinical insights, enabling tailored therapeutic strategies for patients. The company’s commitment to enhancing patient outcomes has garnered recognition within the healthcare community, positioning it as a key player in the evolving landscape of oncology. Through its cutting-edge technology and dedication to research, BostonGene continues to drive advancements in precision medicine, making significant strides in the fight against cancer.
DitchCarbon Score
How does BostonGene Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
BostonGene Corporation's score of 30 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
BostonGene Corporation's reported carbon emissions
In 2023, BostonGene Corporation reported total carbon emissions of approximately 259,000,000 kg CO2e from Scope 1 and 2, alongside a significant Scope 3 total of about 6,894,000,000 kg CO2e. This marks a slight increase in Scope 3 emissions from 2022, which were approximately 6,535,000,000 kg CO2e, while Scope 1 and 2 emissions decreased from about 324,000,000 kg CO2e in the previous year. BostonGene has not established specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to frameworks such as the Science Based Targets initiative (SBTi). The company does not appear to inherit emissions data from a parent organisation, maintaining its own reporting standards. Overall, BostonGene's emissions profile highlights the need for enhanced climate commitments and strategies to address its substantial carbon footprint, particularly in Scope 3 emissions, which represent the majority of its total emissions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | - | - |
| Scope 2 | - | - | - | - | - | - | - |
| Scope 3 | 7,410,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
BostonGene Corporation is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
